Bryan Stuart

August 7, 2020

Bryan Stuart was named president and chief executive officer of Fulcrum Therapeutics in March 2021. He joined Fulcrum as chief operating officer in 2018, bringing over 20 years of industry experience, predominantly in the rare disease space. He has played a leadership role in advancing numerous rare disease programs from the clinic to commercialization. Prior to joining Fulcrum, Bryan was president and CEO of Yarra Therapeutics, a subsidiary of Array BioPharma focused on genetically defined rare diseases. He also served as president and then CEO of Kastle Therapeutics, a biopharmaceutical company focused on developing and commercializing therapeutics for rare diseases. Prior to Kastle, Bryan was chief business officer of Civitas Therapeutics, where he led the business development, capital raising, commercial and portfolio management functions including a planned IPO and eventual sale of the company to Acorda Therapeutics. He also led business development, corporate development and strategy at EKR Therapeutics (acquired by Chiesi) and Ovation Pharmaceuticals (acquired by Lundbeck A/S), where he played key roles in the successful sales of both companies. Bryan began his career as a healthcare investment banker at William Blair & Company. He has an MBA from the Kellogg School at Northwestern University and a bachelor’s degree from the University of Illinois.[/amoteam_text]